V-Wave™ Ventura Interatrial Shunt
HFrEF: A Critical Unmet Need
Approximately 50% of heart failure cases worldwide have reduced LVEF accompanied by progressive left ventricular dilatation and adverse cardiac remodeling.2,3 HFrEF is a major public health concern with substantial morbidity and mortality.2
V-Wave Ventura Interatrial Shunt
For patients with Class III symptomatic heart failure with reduced ejection fraction (HFrEF; LVEF ≤40%), the V-Wave Ventura Interatrial Shunt is designed to reduce increases in left atrial pressure by offloading volume from the left atrium to the right atrium.4
Significant benefit for HFrEF patients1
The decrease in the rate of HFH drove the reduction in heart failure events for HFrEF patients implanted with the shunt.
About Us
V-Wave Ltd., was established in Israel in 2009 with a focus on developing a percutaneous implantable shunt for patients with chronic heart failure. Johnson & Johnson acquired V-Wave on October 9, 2024, and we are now proudly part of Johnson& Johnson MedTech.
References
Stone G, Lindenfeld j, Rodes-Cabau J, et al. Interatrial Shunt Treatment for Heart Failure: The Randomized RELIEVE-HF Trial. Circulation 2024; 150:00–00. DOI: 10.1161/CIRCULATIONAHA.124.070870
Murphy SP, Ibrahim NE, Januzzi JL, Jr. Heart Failure With Reduced Ejection Fraction: A Review. JAMA. Aug 4 2020;324(5):488-504. doi:10.1001/ jama.2020.10262
Golla M, Shams P. Heart failure with preserved ejection fraction (HFpEF). StatLPearls (Internet). StatPearls Publishing; 2025.
Patent numbers: 10251740, 10076403, 11850138 https://ppubs.uspto.gov/pubwebapp/static/pages/ppubsbasic.html
MP-0005741 rev. 2.0